The latest financial statement is for the quarter ending 2025-11-30.
| Cash Flow | 2025-11-30 | 2025-08-31 |
|---|---|---|
| Net loss | 1,597,503 | 11,911,434 |
| Stock based compensation | 74,895 | 859,494 |
| Depreciation and amortization | 16,866 | 87,825 |
| Impairment loss | - | 247,364 |
| Bad debt expense | - | 0 |
| Noncash lease expense | 7,331 | 28,027 |
| Unrealized loss on marketable securities | -22,093 | -33,714 |
| Lease accretion | 1,937 | 9,047 |
| Accounts receivable | -280,314 | 213,881 |
| Prepaid expenses and deposits | -256,919 | -55,313 |
| Long-term receivables | 0 | 438 |
| Accounts payable and accrued liabilities | -37,613 | 396,637 |
| Operating lease liability | -9,337 | -37,093 |
| Deferred revenue | 0 | -4,962 |
| Net cash used in operating activities | -984,098 | -10,450,387 |
| Short-term investments | - | 143,267 |
| Additions to intellectual property | 5,099 | 75,106 |
| Purchase of equipment | 0 | 24,646 |
| Net cash used in investing activities | -5,099 | -243,019 |
| Proceeds from exercise of stock options | - | 0 |
| Proceeds from shares sold for cash | 3,474,051 | 6,046,163 |
| Proceeds from exercise of warrants | - | 0 |
| Net cash provided by financing activities | 3,474,051 | 6,046,163 |
| Effect of exchange rate changes on cash | -5,744 | -50,519 |
| Net change in cash for the period | 2,479,110 | -4,697,762 |
| Cash and cash equivalents at beginning of period | 1,802,123 | 6,499,885 |
| Cash and cash equivalents at end of period | 4,281,233 | 1,802,123 |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)